Organogenesis Holdings financials
$1.39+0.36%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $564.2M | $482.0M | $433.1M | $450.9M | $467.4M | $338.3M | $261.0M | $193.4M |
| Gross profit | $564.2M | $482.0M | $433.1M | $345.9M | $353.2M | $251.0M | $185.0M | $124.6M |
| Gross margin | 100.0% | 100.0% | 100.0% | 76.7% | 75.6% | 74.2% | 70.9% | 64.4% |
| Operating income | $44.7M | -$1.3M | $12.5M | $22.3M | $72.2M | $26.7M | -$29.9M | -$51.6M |
| Net income | $20.0M | -$937.0K | $4.9M | $15.5M | $94.2M | $17.2M | -$38.7M | -$64.8M |
| Net margin | 3.5% | −0.2% | 1.1% | 3.4% | 20.2% | 5.1% | −14.8% | −33.5% |
| Diluted EPS | $0.15 | $-0.01 | $0.04 | $0.12 | $0.70 | $0.15 | $-0.42 | $-0.94 |
| EBITDA | $74.5M | $38.5M | $27.9M | $33.0M | $88.9M | $34.9M | -$20.0M | -$44.6M |
| Operating cash flow | -$10.3M | $14.2M | $30.9M | $24.9M | $66.0M | $5.3M | -$33.5M | -$60.6M |
| Free cash flow | -$24.5M | $4.2M | $6.6M | -$9.0M | $34.7M | -$12.4M | -$39.5M | -$62.5M |
| Diluted shares | 130.2M | 131.7M | 132.7M | 132.4M | 133.7M | 111.4M | 92.8M | 69.3M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $93.7M | $135.6M | $103.8M | $102.5M | $113.9M | $84.4M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | — | — |
| Total debt | $22.2M | $10.2M | $69.2M | $70.8M | $73.6M | $84.8M |
| Total assets | $598.7M | $497.9M | $460.0M | $449.4M | $443.3M | $290.2M |
| Total liabilities | $164.8M | $112.6M | $181.4M | $183.7M | $201.9M | $148.4M |
| Shareholders' equity | $300.1M | $262.9M | $278.7M | $265.7M | $241.3M | $141.8M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology